MDRNA, Inc. announced today that it has entered into an agreement with Roche (Swiss:ROG.SW - News) in which Roche will obtain a non-exclusive license to a portion of MDRNA’s technology platform for the development of RNAi-based therapeutics. Terms of the agreement were not disclosed.
